Wall Street analyst estimates for CVS Health Corp. (CVS): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home.
Consensus price target
$111.25 (+23 % vs price $90.25)
between $92.00 and $123.00 · 9 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $417B | $414B – $422B | $8.05 | 17 |
| 2027E | $430B | $423B – $435B | $8.52 | 18 |
| 2028E | $449B | $425B – $477B | $9.70 | 13 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 2 |
| Buy | 33 |
| Hold | 6 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 41 |
| Avg rating (−2 sell to +2 buy) | 0.90 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $1.66 | ||
| 2026-08-05 | $2.58 | $1.85 | +39.5% |
| 2026-05-06 | $2.57 | $2.18 | +17.9% |
| 2026-02-10 | $1.09 | $1.00 | +9.0% |
| 2025-10-29 | $1.60 | $1.37 | +16.8% |
| 2025-07-31 | $1.81 | $1.46 | +24.0% |
| 2025-05-01 | $2.25 | $1.70 | +32.4% |
| 2025-02-12 | $1.19 | $0.91 | +30.2% |
Valuation Ratios
| P/E Ratio | 23.88 |
| Price / Book | 1.44 |
| EV / EBITDA | 13.45 |
| Dividend Yield | 2.95% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $177.55B | $184.79B | $194.58B | $256.78B | $268.71B | $292.11B | $322.47B | $357.78B | $372.81B | $402.07B |
| Cost of Revenue | $148.71B | $156.26B | $163.04B | $211.25B | $219.66B | $239.99B | $267.96B | $303.35B | $321.41B | $346.70B |
| Gross Profit | $28.83B | $28.53B | $31.54B | $45.53B | $49.05B | $52.12B | $54.50B | $54.43B | $51.40B | $55.36B |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $41.23B | 0 |
| Operating Expenses | $18.45B | $18.99B | $27.52B | $33.54B | $35.13B | $38.81B | $46.55B | $40.69B | $42.88B | $44.98B |
| Operating Income | $10.39B | $9.54B | $4.02B | $11.99B | $13.91B | $13.31B | $7.95B | $13.74B | $8.52B | $10.38B |
| EBITDA | $12.19B | $11.81B | $6.74B | $16.40B | $17.12B | $17.53B | $12.35B | $18.20B | $13.68B | $9.86B |
| Interest Expense | $1.08B | $1.06B | $2.62B | $3.04B | $2.91B | $2.50B | $2.29B | $2.66B | $2.96B | $3.12B |
| Pre-tax Income | $8.64B | $8.27B | $1.41B | $9.00B | $9.77B | $10.54B | $5.84B | $11.17B | $6.15B | $2.14B |
| Income Tax | $3.32B | $1.64B | $2.00B | $2.37B | $2.57B | $2.55B | $1.51B | $2.81B | $1.56B | $408.0M |
| Net Income | $5.32B | $6.62B | -$594.0M | $6.63B | $7.18B | $8.00B | $4.31B | $8.34B | $4.61B | $1.77B |
| EPS | $4.93 | $6.47 | $-0.57 | $5.10 | $5.48 | $6.00 | $3.29 | $6.49 | $3.66 | $1.40 |
| EPS (Diluted) | $4.90 | $6.44 | $-0.57 | $5.08 | $5.46 | $5.95 | $3.26 | $6.47 | $3.66 | $1.39 |
| Shares Outstanding (Diluted) | 1,079.0 M | 1,024.0 M | 1,044.0 M | 1,305.0 M | 1,314.0 M | 1,329.0 M | 1,323.0 M | 1,290.0 M | 1,262.0 M | 1,271.0 M |
Price
| Price | $90.25 (closing price, October 30, 2026) |
| Market Cap | $115.4B |
| Exchange | NYSE |
| Country | US |
Related companies: UNH · CI · ELV · HUM · CNC · MOH · OSCR
Explore sector: Healthcare · Medical - Healthcare Plans
More sections of CVS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks